X-Feed Billboard (International)

The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.

GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.

System-State: Number of processed items 56.787 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
GlobeNewsWire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
AU000000OPT2
State: 13.03.2025 | 1PM
Do you already know our new terminal view? Click here.
FIGI: BBG000BMBF20
CKDXF

Opthea Limited
GICS: - · Sector: Pharmaceuticals, Biotechnology & Life Sciences · Sub-Sector: Biotechnology
NAME
Opthea Limited
ISIN
AU000000OPT2
TICKER
CKDXF
MIC
XASX
REUTERS
OPT.AX
BLOOMBERG
OPT AU
Fri, 28.02.2025       Opthea

Cash and cash equivalents of $131.9M as of December 31, 2024

Fri, 07.02.2025       Opthea

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings.

Wed, 08.01.2025       Opthea

Updates on commercial insights and readiness plans for sozinibercept in wet AMD

Thu, 19.12.2024       Opthea

Business update to include masked Phase 3 patient demographics and baseline characteristics

Tue, 26.11.2024       Opthea

MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.

Fri, 15.11.2024       Opthea

Ms. Connell is a commercial executive with business development expertise

Wed, 16.10.2024       Opthea

Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election

Fri, 30.08.2024       Opthea

Completed patient enrollment in COAST and ShORe pivotal wet AMD trials

Thu, 08.08.2024       Opthea

MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024.

Wed, 17.07.2024       Opthea

Dr. Arshad Khanani to chair the newly formed Medical Advisory Board
Dr. Arshad Khanani to chair the newly formed Medical Advisory Board
Mon, 15.07.2024       Opthea

New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024

Wed, 19.06.2024       Opthea

Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024

Thu, 13.06.2024       Opthea

Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024

Wed, 12.06.2024       Opthea

Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.